Treatment of colorectal liver metastases: A review

Reviews on Recent Clinical Trials

Volumn 4, Issue 1, 2009, Pages 56-62

  Van den Eynde, Marc ^a   Hendlisz, A ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Colorectal liver metastases treatment; Review

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FOLFOX PROTOCOL; FOLFOXIRI PROTOCOL; IFL PROTOCOL; PLATINUM COMPLEX;

ABDOMINAL INFECTION; BILE DUCT FISTULA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DISEASE FREE SURVIVAL; HUMAN; INTERMETHOD COMPARISON; LIVER FAILURE; LIVER METASTASIS; LIVER RESECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; REVIEW; SENSORY NEUROPATHY; SURVIVAL RATE; ADJUVANT THERAPY; CATHETER ABLATION; CLASSIFICATION; COLORECTAL TUMOR; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CATHETER ABLATION; COLORECTAL NEOPLASMS; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 62449325426     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488709787047558     Document Type: Review

References (69)

1. Rastogi T, Hildesheim A, Sinha R. Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer 2004; 4: 909-17.
2. Bouvier AM, Remontet L, Jougla E, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004; 28: 877-81.
3. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br J Surg 1999; 86: 158-69.
4. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189: 496-502.
5. Faivre J, Manfredi S, Bouvier AM. Epidemiology of colorectal cancer liver metastases. Bull Acad Natl Med 2003; 187: 815-22.
6. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for non nonresectable colorectal metastases. Ann Surg Oncol 2001; 8(4): 347-53.
7. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-66.
8. Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected metastases from colorectal cancer. Br J Surg 1995; 82: 1397-1400.
9. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14(Suppl 2): ii13-6.
10. Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355 (9209): 1041-1047.
11. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.
12. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
13. Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
14. Kohne C, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-65.
15. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy, Ann Surg 1996; 224: 509-20 discussion 520-22.
16. Giacchetti S, Itzhaki M, Gruia M, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-9.
17. Tournigand C, Andre T, Achille E, et al. Folfiri followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
18. Folprecht G, Grothey A, Alberts S, Raab H, Kohne C. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-9.
19. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
21. Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88: 980-985.
22. Nordlinger B, Guiguet M, Vaillant J, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-62.
23. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999; 49: 231-255.
24. Alberts S, Horvath W, Sternfeld W, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central cancer treatment group phase II study. J Clin Oncol 2005; 23: 9243-9.
25. Ekberg H, Tranberg K, Andersson R, Jeppsson B, Bengmark S. Major liver resection: perioperative course and management. Surgery 1986; 100:1-8.
26. Steele G, Ravikumar T. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989; 210: 127-38.
27. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005; 12: 900-9.
28. Kokudo N, Miki Y, Sugai S, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002; 137: 833-40.
29. Figueras J, Burdio F, Ramos E, et al. Effect of subcentimeter non-positive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidence from 663 liver resections. Ann Oncol 2007; 18: 1190-5.
30. Wallace J, Christians K, Pitt H, Quebbeman E. Cryotherapy extends the indications for treatment of colorectal liver metastases. Surgery 1999; 126: 766-72 [discussion 772-4].
31. Elias D, Debaere T, Muttillo I, Cavalcanti A, Coyle C, Roche A. Intraoperative use of radiofrequency treatment allows an increase in the rate of curative liver resection. J Surg Oncol 1998; 67: 190-191.
32. Elias D, Baton O, Sideris L, et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 2005; 90: 36-42.
33. Abdalla E, Vauthey J, Ellis L, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-25 discussion 825-827.
34. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-21.
35. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-61.
36. Souglakos J, Ziras N, Polyzos A, et al. Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): preliminary results of a randomized phase III trial. Proc Am Soc Clin Oncol 2004; 23: [Abstr 3532].
37. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25(13): 1670-6.
38. Folprecht G, Lutz M, Schoffski P, et al. Cetuximab and irinotecan/ 5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-6.
39. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO Annual Meeting 2007; Abstr. 4000.
40. Zelek L, Bugat R, Cherqui D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 2003; 14: 1537-42.
41. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-9.
42. Quenet F, Nordlinger B, Rivoire M, et al. Resection of previously unresectable liver metastases from colorectal cancer after chemotherapy with CPT-11/L-OHP/LV5FU (Folfirinox): a prospective phase II trial. Proc Am Soc Clin Oncol 2004; 23: [Abstr 3613].
43. De La Camara J, Rodriguez J, Rotellar F, et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and olinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. J Clin Oncol 2004; 14S: [Abstr 3593].
44. Ho W, Mok T, Ma B, et al. Liver resection after irinotecan (CPT-11), 5-fluorouracil (5FU) and folinic acid (FA) for patients (pts) with unresectable liver metastases (Mets) from colorectal cancer (CRC). Proc Am Soc Clin Oncol 2003; 22: [Abstr 1253].
45. Köhne CH, Van Cutsem E, Wils JA, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol 2003; 22: 254.
46. Giacchetti S, Bjarnason G, Garufi C, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006; 24(22): 3562-9.
47. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer - A GERCOR Study. J Clin Oncol 2006; 24(3): 394-400.
48. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23: 4881-7.
49. Bouchahda M, Tanaka K, Adam R, et al. Three-drug chronotherapy via hepatic artery as salvage treatment for patients with liver only metastases from colorectal cancer. J Clin Oncol 2005; 23: [abstr 3616].
50. Mocellin S, Pilati P, Lise M, Nitti D. Meta-Analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era ? J Clin Oncol 2007; 25: 5649-54.
51. Kerr D, McArdle C, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003; 361: 368-73.
52. Lorenz M, Muller H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18: 243-54.
53. Cohen A, Kemeny N. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003; 8: 553-66.
54. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112-8.
55. Punt C, Tol J, Rodenburg C, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008; 26: (Suppl): [Abstr LBA4011].
56. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-6.
57. Fong Y, Bentrem DJ. CASH (Chemotherapy-Associated Steatohepatitis) costs. Ann Surg 2006; 243(1): 8-9.
58. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24(31): 4983-90.
59. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24: 3939-45.
60. Nordlinger B, Sorbye L, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-16.
61. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 Trial. J Clin Oncol 2006; 24: 4976-82.
62. Kemeny MM, Adak S, Gray B et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002; 20: 1499-505.
63. Tono T, Hasuike Y, Ohzato H, Takatsuka Y, Kikkawa N. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. Cancer 2000; 88: 1549-56.
64. Lygidakis N, Sgourakis G, Vlachos L et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection: Results of a prospective randomized study. Hepatogastroenterology 2001; 48: 1685-91.
65. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-48.
66. Kemeny N, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352: 734-5.
67. Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006; 20: 1161-76, 1179; discussion 1179-1180, 1185-1186.
68. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Colon Cancer v.2. 2008.
69. Baselga J, Rosen N. Determinants of rasistance to anti-epidermal growth factor receptor agents. J Clin Oncol 2008; 26: 1582-4.